缺血性中风和阿尔茨海默病是基因连续的病理吗?
Ivan B Filippenkov1, Andrey V Khrunin1, Ivan V Mozgovoy1
1Laboratory of Human Molecular Genetics, National Research Center "Kurchatov Institute", Kurchatov Sq. 2, 123182 Moscow, Russia.
Biomedicines
|October 28, 2023
概括
本综述探讨了阿尔茨海默病 (AD) 和缺血性中风 (IS) 的共享基因组和RNA生物学. 了解这些联系可能会导致更好的疾病预测和新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 在RNA生物学,RNA生物学.
背景情况:
- 复杂的中枢神经系统疾病,包括阿尔茨海默病 (AD) 和缺血性中风 (IS),对全球健康构成重大挑战.
- 缺血性中风是导致残疾和死亡的主要原因,而阿尔茨海默病是影响生活质量的主要神经退行性疾病.
- 新出现的证据表明,AD和IS之间存在共同的风险因素,致病机制和分子特征.
研究的目的:
- 审查有关缺血性中风和阿尔茨海默病的当前基因组学和RNA生物学研究.
- 阐明AD和IS背后的病理的相互联系.
- 确定潜在的基因组和RNA生物标志物,用于疾病风险预测和治疗开发.
主要方法:
- 关于IS和AD的基因组学研究的综合文献综述.
- 分析RNA生物学研究,重点关注共享的分子通路.
- 综合发现,突出共同的遗传和分子基础.
主要成果:
- 在IS和AD之间识别重叠的基因组架构.
- 在两种疾病中涉及的共享分子特征和RNA分子的表征.
- 证据支持常见的致病因素导致神经退行和脑血管事件.
结论:
- IS和AD的共同基因组和RNA生物学表明有一个共同的病因基础.
- 特定的基因组位置和RNA分子代表了未来诊断和治疗干预的有希望的目标.
- 对这些共同机制的进一步研究对于推进这些复杂神经系统疾病的管理至关重要.
更多相关视频
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.0K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
相关概念视频
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
